Levi & Korsinsky notifies investors that it has commenced an investigation into Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) concerning potential violations of the federal securities laws.
Zentalis issued a press release on January 28, 2025, "announc[ing] a restructuring of its business operations and research and development organization to support execution of late-stage development for its WEE1 inhibitor product candidate, azenosertib, and extend its cash runway beyond a data readout from its potentially registration-enabling DENALI Part 2 study, anticipated by the end of 2026." Zentalis stated that "[t]he workforce reduction is expected to be substantially completed in the second quarter of 2025." Following this news, Zentalis's stock price fell sharply during intraday trading on January 29, 2025.
If you suffered a loss on your Zentalis Pharmaceuticals, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





